ClinicalTrials.gg
WithdrawnNCT00786734Updated Mar 30, 2012

Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)

A Phase 4 interventional study of Pitavastatin and Pitavastatin in Percutaneous Coronary Intervention, sponsored by JW Pharmaceutical. Withdrawn at 1 site in Korea, Republic of. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-03-30.

Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Angina, Stable with a site in Korea, Republic of — 1 open to participants now, 5 under way, none of them phase 3. Angina, Stable · Korea, Republic of.

Enrollment
24th of 24
0 · median 114
Started
2008
the only one that year
Phase 4
11 of 30
none open now
Registered
1st of 30
by date

Among the 30 studies in Angina, Stable with a site in Korea, Republic of, this one is the 24th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2008, is one of 11 in phase 4, and was the 1st registered.

Angina, Stable

344 studies on the registry are indexed under Angina, Stable; 57 are open to participants now.

Browse Angina, Stable studies →

Open to participants now

1 of the 30 studies in Angina, Stable with a site in Korea, Republic of is open now. Recruiting first, the newest first:

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 39 Angina, Stable studies recruiting now, 33 (85%) set no upper age limit and 2 (5%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Angina, Stable with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Patients who is scheduled elective PCI are randomized to pitavastatin 4mg daily or without pitavastatin for 5 -7days before the procedure. Creatine kinase-MB, troponin I, and myoglobin levels are measured at baseline and at 8 and 24 hours after the procedure(1st evaluation). After PCI, pitavastatin will be administered for additional 4 weeks(2nd evaluation).

Read the detailed description

Procedural ischemic myocardial injury remains the most frequent complication after coronary angioplasty. Recently it was reported that pretreatment with atorvastatin reduce the myocardial damage compared to placebo. Thus, we will evaluate the difference of pretreatment of pitavastatin compared to standard therapy on the reduction of myocardial damage in patient who is scheduled elective PCI for stable angina pectoris.

03

Conditions studied

  • Percutaneous Coronary Intervention

Browse trials for

Keywords

  • pitavastatin
  • PCI
  • stable angina
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with LDL ≥ 100mg/dL
  • Patients who are scheduled an elective PCI for stable angina

Exclusion criteria

Exclusion Criteria:

  • Acute myocardial infarction (\<3 months)
  • Unstable angina
  • Previous treatment with statins (\<6 months)
  • Increase in CK-MB above upper normal limit
  • Increase in liver enzymes (/ALT) above 2 times of upper normal limit
  • Increase in serum creatinine above 2 times of upper normal limit
  • \<30%
  • Previous treatment with glycoprotein Ⅱb/Ⅲa receptor inhibitor (\<4 weeks)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Pitavastatin Group

    Drug: Pitavastatin

  • Other
    Usual Care Group

    Drug: Pitavastatin

Interventions

  • 4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI

  • 4mg daily for 28 days after PCI

06

What researchers measure

Primary outcomes

  1. Proportion of patients whose CK-MB > 2 times above UNL

    Time frame: First evaulation time (before PCI)

Secondary outcomes

  1. Proportion of patients who show any increase of CK-MB, troponin I, and myoglobin above UNL

    Time frame: First evaluation time

  2. Mean peak values of CK-MB, troponin I and myoglobin after intervention

    Time frame: After PCI (<24hrs)

  3. Change of hs-CRP, wall motion score

    Time frame: Second evaluation time

  4. Occurence of all major adverse cardiac events

    Time frame: Second evaluation time

07

Study locations

1 site
  • Catholic University of Korea Kangnam St. Mary's Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of May 2009 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2008
First posted
Nov 6, 2008
Start
Aug 2008
Primary completionActual
May 2009
CompletionActual
Jul 2010
Last update
Mar 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00786734
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Nov 6, 2008
Start date
Aug 2008
Primary completion
May 2009
Completion
Jul 2010
Last update
Mar 30, 2012

Study contacts

Ki Bae Seung, Ph.D
principal investigator · Professor, Catholic University of Korea Kangnam St. Mary's Hospital located

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion